Clinical Trial Design that Maximizes Biomarker-Driven Insights
Intuitive, biomarker-driven clinical trials, designed with Precision
Contact us
Patient populations can be refined, rather than randomized, based on umbrella or basket designs, depending on the nature of the study drug and relevant indications as well as the different types of clinical research being performed. Our team of Precision experts focuses on protocol nuances to match each patient with the optimal study population and gain valuable insights from biomarkers. This results in a “rapid-to-market” strategy precisely tailored to your product.
.jpg?width=343&height=396&name=iStock-1177064020%20(1).jpg)
Master Protocol Trials
We stay at the forefront of clinical trial design, pairing statistical rigor and biomarker expertise to design and implement master protocol trials.
.png?width=2000&name=PDF-pg34-(1).png)
Informed by biomarkers.
Designed for insights.
Biomarker-driven science seamlessly integrated with clinical development.
A precision-driven approach ensures that robust molecular-level data positions the right patient with the right drug. With our expertise in translational medicine and clinical trial execution, every trial design is informed by advanced biomarkers and is purpose-built for improved insights and streamlined trial execution.
Integrated solutions can optimize your study’s strategy and trial design. Harnessing the efficiency of biomarker-driven studies not only accelerates the trial process but also ensures that Precision delivers clinical developments faster and with greater insight compared to conventional trial designs.
Case Study
Download case study
A basket trial and an accelerated pathway to proof-of-concept
As part of a long-term collaboration, Precision for Medicine used an adaptive approach to explore multiple tumor types concurrently, accelerating the pathway to proof-of-concept.
Targeted patient:
The study targets subjects with a specific rare mutation. The protocol identifies a list of possible mutations. All patients are required to have genomic assays completed with the mutation identified before enrollment will be considered.
Study design:
The initial protocol had 8 different tumor-specific mutation cohorts in a Simon’s 2-stage design. For the first stage, 7 patients are enrolled; if 1 response is observed the cohort expands to stage 2. If no responses are identified, the cohort may be closed, with new tumor types identified. Tumor types are ruled “in” for further exploration (up to the point of accelerated approval or phase 3 investment) or “out” within this trial.
Download this case study to learn more.
Insights from Precision’s experts
Stay ahead with the latest insights from Precision’s team of experts. Discover valuable perspectives, updates, and strategies to design optimal global clinical programs.
Lean Authoring: Bringing Efficiency and Speed to Clinical Study Reports
What Is an FDA Breakthrough Therapy Designation?
Specialized capabilities in every stage of clinical development
Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to increase speed to market. Incorporate manufacturing expertise for advances therapies to ensure scalability. Precision can customize and converge our capabilities for your program's unique needs.
-
Discover Explore
Global CRO
ServicesAward-winning CRO with deep oncology and rare disease expertise
-
Discover Explore
Global Laboratory
ServicesExceptional translational and biomarker sciences with global central lab services
-
Discover Explore
Manufacturing
SolutionsPioneers in planning, building and maintaining manufacturing at scale for pharma and biotechs.
-
Discover BiospecimensBiospecimens
-
Discover Diagnostics & CDxDiagnostics & CDx
-
Discover Data IntelligenceData Intelligence
-
Discover CommercializationCommercialization
